Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus
Disclosed is a vaccine antigen capable of inducing a cross-reacting and neutralizing antibody directed against a high-risk-type human papillomavirus. Specifically disclosed are: a chimeric protein comprising an L2-epitope of a human papillomavirus (HPV) type-16 inserted in a loop region of a human papillomavirus type-16 L1 protein; and a capsid which is a particle formed by the chimeric protein. The loop region to which the L2-epitope is to be inserted is located between an amino acid residue at position-430 and an amino acid residue at position-433. The L2-epitope has an amino acid sequence represented by any one of the following formulae: LYKTCKQAGTCPPDIIPKVEG (SEQ ID NO: 2) (18-38 L2-epitope); GGLGIGTGSGTGGRTGYIPL (SEQ ID NO: 3) (56-75 L2-epitope); and DPVGPLDPSIVSLVEESSFI (SEQ ID NO: 4) (96-115 L2-epitope).
1. A capsid which is an aggregate formed by assembly of chimeric protein composed of human papillomavirus (HPV) 16 L1 protein and an HPV16 L2 epitope inserted in the loop region of the HPV16 L1 protein, wherein
the region for insertion of the L2 epitope is a region of amino acids 430 to 433 and
the L2 epitope has an amino acid sequence represented by:
GGLGIGTGSGTGGRTGYIPL (SEQ ID NO: 3) (hereinafter, referred to as 56-75 L2 epitope).
2. The capsid according to claim 1 , wherein the aggregate is an aggregate formed by assembly of multiple pentamer capsomeres, wherein each pentamer capsomere is composed of five chimeric protein molecules.
3. The capsid according to claim 2 , wherein the aggregate formed by assembly of multiple pentamer capsomeres has a particle structure.
4. The capsid according to claim 3 , wherein the number of the pentamer capsomeres constituting the aggregate is in the range of 65 to 80.
5. The capsid according to claim 3 , wherein the number of the pentamer capsomeres constituting the aggregate is 72.
6. The capsid according to any one of claims 1 and 2 to 5 , which is used for production of an L1 capsid immunogenic composition.
7. A chimeric protein composed of human papillomavirus (HPV) 16 L1 protein and an HPV16 L2 epitope inserted in the loop region of the HPV16 L1 protein, wherein
the loop region for insertion of the L2 epitope is a region of amino acids 430 to 433, and
the L2 epitope has an amino acid sequence represented by:
GGLGIGTGSGTGGRTGYIPL (SEQ ID NO: 3) (hereinafter, referred to as 56-75 L2 epitope).
8. A method of producing the capsid according to any one of claims 1 and 2 to 5 , wherein the capsid is formed by assembly of the chimeric protein according to claim 7 .